{"product_id":"venoruton-500mg-30-compresse-rivestite","title":"Venoruton 500mg 30 coated tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVENORUTON is indicated in the treatment of symptoms related to venous insufficiency; states of capillary fragility.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eVenoruton 1000 mg powder\u003c\/u\u003e: One sachet contains - Active ingredient: oxerutin 1000 mg. \u003cu\u003eVenoruton 500 mg coated tablets\u003c\/u\u003e: One tablet contains: Active ingredient oxerutin 500 mg. Excipients with known effects: sunset yellow aluminum lake (E 110) (2.68 mg\/tablet). \u003cu\u003eVenoruton 2% gel\u003c\/u\u003e: 100 g of gel contains: Active ingredient oxerutin 2 g. Excipients with known effects: benzalkonium chloride 0.05 mg\/g. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eVenoruton 1000 mg powder\u003c\/u\u003e: mannitol; sodium saccharin; citric acid monohydrate. \u003cu\u003eVenoruton 500 mg coated tablets\u003c\/u\u003e: polyacrylate dispersion 30 percent; talc; magnesium stearate; macrogoli; copovidone; \u003cb\u003esunset yellow aluminum lacquer (E 110)\u003c\/b\u003e; titanium dioxide. \u003cu\u003eVenoruton 2% gel for cutaneous use:\u003c\/u\u003e carbomers; sodium hydroxide; disodium edetate; \u003cb\u003ebenzalkonium chloride\u003c\/b\u003e; purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eVenoruton 1000 mg powder\u003c\/u\u003e: 2 to 3 sachets per day, depending on the severity of the symptom. The contents of each sachet of powder should be carefully dissolved in a little water and taken before or during meals, even in venous insufficiency of the hemorrhoidal plexus. \u003cu\u003eVenoruton 500 mg coated tablets\u003c\/u\u003e: 2 - 3 tablets per day. The tablets should be swallowed whole with a little water, without chewing, before or during meals, even in venous insufficiency of the haemorrhoidal plexus. \u003cu\u003eVenoruton 2% gel for cutaneous use\u003c\/u\u003e: apply an adequate quantity of gel both on the area affected by the disorder and on the surrounding areas, 2 times a day (morning and evening). Massage lightly to allow the medicine to penetrate until completely absorbed, that is, until the skin feels dry upon contact with your hands. Do not exceed the recommended doses. Use only for short treatment periods.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePatients suffering from lower limb edema due to heart, kidney or liver disease should not take Venoruton as the effect of Venoruton is not demonstrated in these indications. Pediatric population The use of Venoruton is not recommended in children. \u003cu\u003eVenoruton gel\u003c\/u\u003e: The use, especially if prolonged, of products to be applied to the skin can give rise to sensitization phenomena. In this case you should stop treatment and contact your doctor to institute suitable therapy. \u003cb\u003e \u003ci\u003eImportant information about some excipients\u003c\/i\u003e \u003c\/b\u003e Venoruton 1000 mg powder contains: - sodium saccharin: this medicinal product contains less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'. Venoruton 500 mg film-coated tablets contain the azo coloring agent: - sunset yellow aluminum lake (E 110): may cause allergic reactions. Venoruton gel contains: - benzalkonium chloride: this medicinal product contains 0.391 mg of benzalkonium chloride per dose equivalent to 0.05 mg\/g. Benzalkonium chloride may irritate the skin. If you are breastfeeding, do not apply this medicine to your breasts because your baby may ingest it with his milk.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTo date, no specific interaction of oxerutin with other medicinal products has been reported. In vitro data on a possible modulation of CYP3A activity by oxerutin components (quercetin and rutin present in trace amounts) are conflicting. Venoruton gel: no interactions with medicinal products have been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVenoruton oral formulations: \u003cb\u003eSafety profile summary \u003c\/b\u003e Venoruton may in rare cases cause gastrointestinal side effects or skin reactions such as gastrointestinal disorders, flatulence, diarrhoea, abdominal pain, stomach discomfort, dyspepsia, rash, itching or hives. Very rare is the appearance of dizziness, headache, hot flashes, tiredness or hypersensitivity reactions such as anaphylactoid reactions. \u003cb\u003eTable of adverse reactions \u003c\/b\u003e Side effects are listed below by system organ class and frequency. Frequencies are defined as: very common (≥ 1\/10), common (≥ 1\/100 to \u003c 1\/10); uncommon (≥ 1\/1,000 to \u003c 1\/100); rare (≥ 1\/10,000 to \u003c 1,000); very rare (\u003c 1\/10,000), or not known (frequency cannot be estimated from the available data). Within each frequency class, undesirable effects are indicated in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare - Adverse reactions: Anaphylactoid reactions.\u003c\/p\u003e\n\u003cp\u003eVery rare - Adverse reactions: Hypersensitivity reactions\u003c\/p\u003e\n\u003cp\u003eNervous system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare - Adverse reactions: Dizziness.\u003c\/p\u003e\n\u003cp\u003eVery rare - Adverse reactions: Headache.\u003c\/p\u003e\n\u003cp\u003eVascular pathologies.\u003c\/p\u003e\n\u003cp\u003eVery rare - Adverse reactions: Flushing.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eRare - Adverse reactions: Gastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eRare - Adverse reactions: Flatulence.\u003c\/p\u003e\n\u003cp\u003eRare - Adverse reactions: Diarrhoea.\u003c\/p\u003e\n\u003cp\u003eRare - Adverse reactions: Abdominal pain.\u003c\/p\u003e\n\u003cp\u003eRare - Adverse reactions: Stomach disorders.\u003c\/p\u003e\n\u003cp\u003eRare - Adverse reactions: Dyspepsia.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eRare - Adverse reactions: Rash.\u003c\/p\u003e\n\u003cp\u003eRare - Adverse reactions: Pruritus.\u003c\/p\u003e\n\u003cp\u003eRare - Adverse reactions: Urticaria.\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eVery rare - Adverse reactions: Tiredness.\u003c\/p\u003e\n\u003cp\u003eVenoruton gel: \u003cb\u003eSafety profile summary\u003c\/b\u003e Venoruton gel is well tolerated. Rare cases of sensitization with the appearance of skin reactions have been observed. These symptoms disappear when treatment is stopped. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo case of overdose has ever been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e The safety of the drug in pregnancy has not been determined, therefore it is not recommended during pregnancy. \u003cu\u003eBreastfeeding\u003c\/u\u003e In animal studies, traces of oxerutin have been found in breast milk. It is assumed that the small quantities of oxerutin that pass into breast milk can be considered to have no clinical relevance for humans. \u003cu\u003eFertility\u003c\/u\u003e Animal studies have shown no effects on fertility after administration of oxerutin.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVenoruton has no or negligible influence on the ability to drive or use machines. In rare cases, tiredness and dizziness have been reported in patients taking the product. Affected patients are advised not to drive or use machinery. Venoruton gel does not alter the ability to drive and use machines.\u003c\/p\u003e","brand":"Eg","offers":[{"title":"Default Title","offer_id":51131360248135,"sku":"017076148","price":16.34,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/eg-spa-venoruton-500mg-30-compresse-rivestite-farmacia-dottor-tili-1213791932.jpg?v=1767141587","url":"https:\/\/www.dottortili.com\/en-eu\/products\/venoruton-500mg-30-coated-tablets","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}